CXCL8 and hematopoietic and lymphoid cell neoplasm: We observed that CXCL8 (AUC 0.98) and VEGFA (AUC 0.94) were particularly good at predicting COVID-19 outcomes within hematologic cancer patients (Figure 8C), while CXCL8 (AUC 0.89) and IL-6 (AUC 0.88) were good predictors for solid tumor patients (Figure 8D).